Skip to main content
Journal cover image

Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Publication ,  Journal Article
Chan, A; Patel, K; Naggie, S
Published in: Drugs
February 2017

Hepatitis C virus (HCV) represents a significant global disease burden, with an estimated 130-150 million people worldwide living with chronic HCV infection. Within the six major clinical HCV genotypes, genotype 3 represents 22-30% of all infection and is described as a unique entity with higher rates of steatosis, faster progression to cirrhosis, and higher rates of hepatocellular carcinoma. Hepatic steatosis in the setting of hepatitis C genotype 3 (HCV-3) is driven by viral influence on three major pathways: microsomal triglyceride transfer protein, sterol regulatory element-binding protein-1c, and peroxisome proliferator-associated receptor-α. Historically with direct-acting antivirals, the rates of cure for HCV-3 therapies lagged behind the other genotypes. As current therapies for HCV-3 continue to close this gap, it is important to be cognizant of common drug interactions such as acid-suppressing medication and amiodarone. In this review, we discuss the rates of steatosis in HCV-3, the mechanisms behind HCV-3-specific steatosis, and current and future therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Drugs

DOI

EISSN

1179-1950

Publication Date

February 2017

Volume

77

Issue

2

Start / End Page

131 / 144

Location

New Zealand

Related Subject Headings

  • Pharmacology & Pharmacy
  • Humans
  • Hepatitis C
  • Hepacivirus
  • Genotype
  • Fatty Liver
  • Antiviral Agents
  • 3214 Pharmacology and pharmaceutical sciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chan, A., Patel, K., & Naggie, S. (2017). Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs, 77(2), 131–144. https://doi.org/10.1007/s40265-016-0685-x
Chan, Austin, Keyur Patel, and Susanna Naggie. “Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Drugs 77, no. 2 (February 2017): 131–44. https://doi.org/10.1007/s40265-016-0685-x.
Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017 Feb;77(2):131–44.
Chan, Austin, et al. “Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Drugs, vol. 77, no. 2, Feb. 2017, pp. 131–44. Pubmed, doi:10.1007/s40265-016-0685-x.
Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017 Feb;77(2):131–144.
Journal cover image

Published In

Drugs

DOI

EISSN

1179-1950

Publication Date

February 2017

Volume

77

Issue

2

Start / End Page

131 / 144

Location

New Zealand

Related Subject Headings

  • Pharmacology & Pharmacy
  • Humans
  • Hepatitis C
  • Hepacivirus
  • Genotype
  • Fatty Liver
  • Antiviral Agents
  • 3214 Pharmacology and pharmaceutical sciences
  • 3202 Clinical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences